Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced a new addition to its Board of Directors: Tim Walbert. The company is also noting the upcoming departure of current director Niall O’Donnell, Ph.D., who has elected to step down from the Board of Directors in connection with the 2023 Annual Meeting of Stockholders, scheduled for June 12th, 2023.
Tim Walbert has made a major impact on the biotechnology and pharmaceutical industries, having served in a variety of senior roles since 1991. After 15 years as president, CEO, and chairman of the board of Horizon Therapeutics, which was recently acquired by Amgen, Walbert has joined Mirum’s board.
Prior to Horizon, Walbert was president, CEO and a director of IDM Pharma Inc., which was acquired by Takeda America Holdings Inc. in 2009, and executive vice president, commercial operations at NeoPharm Inc.
He also held leadership roles at Abbott, now AbbVie, where he led the global development and launch of the multi-indication biologic HUMIRA, and at G.D. Searle & Company, Merck & Co. Inc. and Wyeth. With Walbert’s extensive experience and impressive track record, Mirum is thrilled to welcome him to the board.
Mr. Walbert is an experienced board member, currently serving on the board of Century Therapeutics, a public biotech company, and the National Organization for Rare Disorders (NORD) Advisory Board. He is also a member of the Wall Street Journal CEO Council and the Board of Trustees of Muhlenberg College.
His previous board experience includes Aurinia Pharmaceuticals, Exicure, Assertio, Raptor Pharmaceutical Corp., XOMA Corporation, and Sucampo Pharmaceuticals Inc.
He is also a member of the Economic Club of Chicago, the Commercial Club of Chicago, and the Civic Committee of the Commercial Club of Chicago, as well as former board member of the Biotechnology Innovation Organization (BIO), the Pharmaceutical Research and Manufacturing Association (PhRMA), the Illinois Biotechnology Innovation Organization (iBIO), and World Business Chicago. Mr. Walbert holds a Bachelor of Arts in business from Muhlenberg College.
The Mirum board of directors is delighted to welcome Tim Enstice to the team as the new CEO. With extensive experience in the rare disease and pharmaceutical industry, Tim brings unparalleled enthusiasm, knowledge, and insight to the role.
His dedication to advancing patient care and creating value for shareholders is a tremendous asset to the company. The board would like to extend their appreciation to Niall for his invaluable guidance in helping establish Mirum as a leading global organization in rare and orphan diseases.
I am thrilled to join Mirum’s board at such an exciting time for the company. Mirum is well-positioned for continued growth and success, with an impressive team, a promising pipeline, and many successful clinical and commercial achievements. I am eager to use my experience in rare diseases and global launches to help take Mirum to the next level and bring transformative therapies to patients in need.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company on a mission to revolutionize the treatment of rare liver diseases. This is exemplified by their approval of LIVMARLI® (maralixibat) oral solution, which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome three months of age and older, and in Europe for the same indication in patients two months of age and older.
Mirum has also submitted LIVMARLI for approval in the U.S. (in cholestatic pruritus in PFIC for patients three months and older) and in Europe (in PFIC for patients two months and older), furthering their commitment to making a real difference in the lives of those with rare liver diseases.
Mirum’s late-stage pipeline is revolutionizing the way liver diseases are treated. Their investigational treatments, LIVMARLI and expanded access program, are giving hope to patients suffering from debilitating liver diseases.
LIVMARLI, an oral ileal bile acid transporter (IBAT) inhibitor, is being evaluated in clinical trials for pediatric liver diseases, such as the EMBARK Phase 2b clinical trial for patients with biliary atresia. Additionally, their expanded access program is open across multiple countries for eligible patients with ALGS and PFIC.
Mirum Pharmaceuticals is conducting two potentially registrational studies on their investigational treatment, volixibat, an oral IBAT inhibitor. The VISTAS Phase 2b clinical trial is evaluating the treatment in adults with primary sclerosing cholangitis, while the VANTAGE Phase 2b clinical trial aims to assess its efficacy in adults with primary biliary cholangitis. This research marks an exciting step forward in the development of an innovative treatment for these conditions.